MET Exon 14 Skipping and Actionable Variants in Lung Cancer
Author Information
Author(s): Solange Rivas, Romina V. Sepúlveda, Ignacio Tapia, Catalina Estay, Vicente Soto, Alejandro Blanco, Evelin González, Ricardo Armisen, Bruna Scaggiante
Primary Institution: Centro de Genética y Genómica, Instituto de Ciencias e Innovación en Medicina, Facultad de Medicina Clínica Alemana Universidad del Desarrollo, Santiago, Chile
Hypothesis
How many RNA reads are necessary to achieve a successful therapeutic response to MET inhibitors in NSCLC patients?
Conclusion
The study highlights the importance of RNA-based METex14 diagnosis and reveals the drug sensitivity profiles of novel actionable MET variants in Latin American patients.
Supporting Evidence
- 8% of the South American cohort had MET variants, compared to 4% in the GENIE cohort.
- RNA-based diagnosis detected 27% more cases of METex14 than DNA-based methods.
- 20% of METex14 cases with RNA reads below the detection threshold were confirmed using DNA analysis.
- T992I and H1094Y variants induced proliferation and migration through c-Met/Akt signaling.
- Both variants showed sensitivity to crizotinib and savolitinib.
Takeaway
This study looked at lung cancer patients in South America and found new genetic changes that could help doctors choose better treatments.
Methodology
The study used a 52-gene next-generation sequencing panel to analyze tumor biopsies and assessed the pathogenicity of MET variants using bioinformatic methods.
Potential Biases
Potential bias due to the underrepresentation of non-Caucasian populations in existing research on actionable variants.
Limitations
The study primarily focused on a South American cohort, which may limit the generalizability of the findings to other populations.
Participant Demographics
71.3% from Chile, 20.4% from Brazil, and 7.4% from Peru; average age 66; 53.7% women and 46.3% men.
Statistical Information
P-Value
0.02
Statistical Significance
p=0.02
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website